At the recent American Society of Hematology (ASH) virtual meeting, a number of important trial updates in multiple myeloma were presented, and MedPage Today brought together three expert leaders in their field: moderator Vinay Prasad, MD, is joined by Aaron Goodman, MD, and Al-Ola Abdallah, MD, for a virtual roundtable discussion on the new and potentially practice-changing data from the meeting.
In episode one, the physicians debated the follow-up analysis of a trial that questioned the necessity of early versus delayed ASCT, in light of newer therapies we have today.
In episode two, Dr. Prasad asked if selinexor, recently approved with support from the phase III BOSTON study, a good drug for the treatment of adults with multiple myeloma who have received at least one prior therapy?
Questions surrounding the phase II GRIFFIN study, which assessed the addition of daratumumab into the lenalidomide, bortezomib, and dexamethasone (RVd) backbone for transplant-eligible newly diagnosed patients with multiple myeloma, was the focus of episode three.
The roundtable discussion turned to the FORTE trial in episode four, debating whether the positive results should mean adding more potentially toxic and expensive treatments to standard of care.
And in episode five, the physicians wrap up their discussion with the lingering questions that surround the many novel studies from the meeting that are investigating chimeric antigen receptor (CAR) T-cell therapy.
Last Updated January 29, 2021